650 related articles for article (PubMed ID: 30095317)
1. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.
Fang CY; Liu CC
Expert Rev Vaccines; 2018 Sep; 17(9):819-831. PubMed ID: 30095317
[TBL] [Abstract][Full Text] [Related]
2. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
3. Is a multivalent hand, foot, and mouth disease vaccine feasible?
Klein M; Chong P
Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
[TBL] [Abstract][Full Text] [Related]
4. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
Mao Q; Wang Y; Bian L; Xu M; Liang Z
Emerg Microbes Infect; 2016 Jul; 5(7):e75. PubMed ID: 27436364
[TBL] [Abstract][Full Text] [Related]
5. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
Lim H; In HJ; Lee JA; Sik Yoo J; Lee SW; Chung GT; Choi YK; Chung JK; Cho SJ; Lee JW
Vaccine; 2018 Jun; 36(24):3445-3452. PubMed ID: 29739716
[TBL] [Abstract][Full Text] [Related]
6. Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease.
Anasir MI; Poh CL
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871133
[TBL] [Abstract][Full Text] [Related]
7. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China.
Jiang H; Zhang Z; Rao Q; Wang X; Wang M; Du T; Tang J; Long S; Zhang J; Luo J; Pan Y; Chen J; Ma J; Liu X; Fan M; Zhang T; Sun Q
Emerg Microbes Infect; 2021 Dec; 10(1):619-628. PubMed ID: 33682641
[TBL] [Abstract][Full Text] [Related]
8. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems.
Bian L; Gao F; Mao Q; Sun S; Wu X; Liu S; Yang X; Liang Z
Expert Rev Anti Infect Ther; 2019 Apr; 17(4):233-242. PubMed ID: 30793637
[TBL] [Abstract][Full Text] [Related]
9. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.
Zhao H; Li HY; Han JF; Deng YQ; Zhu SY; Li XF; Yang HQ; Li YX; Zhang Y; Qin ED; Chen R; Qin CF
Sci Rep; 2015 Jan; 5():7878. PubMed ID: 25597595
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Coxsackievirus A5 Vaccine Candidates in an Actively Immunized Mouse Model.
Jin WP; Lu J; Zhang XY; Wu J; Wei ZN; Mai JY; Qian SS; Yu YT; Meng SL; Wang ZJ; Shen S
J Virol; 2021 Feb; 95(6):. PubMed ID: 33408178
[TBL] [Abstract][Full Text] [Related]
11. Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies.
Fang CY; Liu CC
Expert Opin Drug Discov; 2022 Jan; 17(1):27-39. PubMed ID: 34382876
[TBL] [Abstract][Full Text] [Related]
12. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
Vaccine; 2016 Nov; 34(48):5938-5945. PubMed ID: 27771182
[TBL] [Abstract][Full Text] [Related]
13. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
[TBL] [Abstract][Full Text] [Related]
14. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
Liu CC; Chow YH; Chong P; Klein M
Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
[TBL] [Abstract][Full Text] [Related]
15. Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy.
Aswathyraj S; Arunkumar G; Alidjinou EK; Hober D
Med Microbiol Immunol; 2016 Oct; 205(5):397-407. PubMed ID: 27406374
[TBL] [Abstract][Full Text] [Related]
16. Enterovirus spectrum from the active surveillance of hand foot and mouth disease patients under the clinical trial of inactivated Enterovirus A71 vaccine in Jiangsu, China, 2012-2013.
Yao X; Bian LL; Lu WW; Li JX; Mao QY; Wang YP; Gao F; Wu X; Ye Q; Xu M; Li XL; Zhu FC; Liang ZL
J Med Virol; 2015 Dec; 87(12):2009-17. PubMed ID: 26010334
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
18. The spatial-temporal distribution and etiological characteristics of hand-foot-and-mouth disease before and after EV‑A71 vaccination in Kunming, China, 2017-2020.
Wang M; Chen T; Peng J; Luo Y; Du L; Lu Z; He J; Liu C; Gan Q; Ma W; Cun Z; Zheng Q; Chen W; Chen Y; Han M; Liu G; Li J
Sci Rep; 2022 Oct; 12(1):17028. PubMed ID: 36220850
[TBL] [Abstract][Full Text] [Related]
19. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine.
Zhou Y; Li JX; Jin PF; Wang YX; Zhu FC
Expert Rev Vaccines; 2016 Jul; 15(7):803-13. PubMed ID: 27206811
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological surveillance of hand, foot and mouth disease in Shanghai in 2014-2016, prior to the introduction of the enterovirus 71 vaccine.
Li J; Pan H; Wang X; Zhu Q; Ge Y; Cai J; Li Y; Xia A; Hu J; Zeng M
Emerg Microbes Infect; 2018 Mar; 7(1):37. PubMed ID: 29559626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
